Cost Efficiency vs. Control: Strategic Trade-Offs in U.S.-Based Discovery Outsourcing
The U.S. small molecule drug discovery outsourcing market, valued at USD 1.49 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 9.48% from 2025 to 2034, driven by escalating R&D costs, talent scarcity, and the pharmaceutical industry’s strategic shift toward externalized innovation. As biopharma companies face mounting pressure to accelerate drug...
0 Комментарии
0 Поделились